Since the current treatment of this lymphoma (mainly based on aggressive chemotherapy) is not optimal, as 30% of the patients relapse five years post-treatment, considerable efforts have been made to develop therapies directly targeting the NPM-ALK oncoprotein. Here, ALK is linked to lymphoma.